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Congenital long QT syndrome (LQTS) is a familial disorder characterized by 
ventricular repolarization that makes carriers vulnerable to malignant ventricular 
tachycardia, torsade de pointes, and sudden cardiac death. The most common 
subtypes, LQT1 and LQT2, are caused by loss-of-function mutations in slow (IKs) 
and fast (IKr) cardiac potassium channels, whereas subtype LQT3 is caused by 
gain-of-function mutations in cardiac sodium channel (INa). The disorder is 
characterized by a prolonged QT interval in electrocardiograms (ECG), but a 
considerable portion are silent carriers presenting normal (QTc <440 ms) or 
borderline (QTc <470 ms) QT interval, making the diagnosis challenging. Genetic 
testing is available for 60-70% of patients, leaving the rest without definite 
diagnosis. However, identifying affected asymptomatic relatives before their first 
attack may have a life-saving outcome. A number of pharmaceutical compounds 
also have affinity to the cardiac IKr channel, causing a clinically similar disorder 
called acquired long QT syndrome. LQTS carriers - who already have impaired 
ventricular repolarization - are especially vulnerable. For example, they are usually 
not included in clinical safety studies. Our aim was to create methods to improve 
the diagnosing of silent LQTS carriers. A method for accurate QT interval 
measurement was developed and the effects of antihistamine cetirizine on 
ventricular repolarization was studied.   
 
We studied a total of 49 subjects with LQTS: 22 in the LQT1 group, 17 in LQT2 
and 10 in LQT3. All were asymptomatic genotyped carriers of different LQTS-
causing mutations, and all had a normal or only marginally prolonged QT interval 
in resting ECG. In addition, 32 healthy controls were studied. The body surface 
potential mapping (BSPM) system was utilized for ECG recording, and signals 
were analyzed with an automated analysis program. Resting QT intervals were 
adjusted for heart rate by Bazett’s formula (QTc), otherwise intervals were 
compared without correction formulas. In addition to QT interval length, the end 
part of the T wave, the Tpe interval, was studied during exercise stress testing and 
an epinephrine provocation test. In the latter, T wave morphology was also 
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analyzed. The effect of cetirizine on ventricular repolarization was studied in LQT1 
and LQT2 carriers and also with supra- therapeutic dose in healthy volunteers. 
 
LQTS mutation carriers had slightly longer QTc intervals than healthy subjects 
(427 ± 31 ms and 379 ± 26 ms; p<0.001), but significant overlapping existed. 
LQT2 mutation carriers had a conspicuously long Tpe-interval (113 ± 24 ms; 
compared to 79 ± 11 ms in LQT1, 81 ± 17 ms in LQT3 and 78 ± 10 ms in controls; 
p<0.001). In repeated exercise tests, the method for QT and Tpe interval 
measurements was accurate and highly repeatable. In exercise stress tests, LQT1 
mutation carriers exhibit a long QT interval at high heart rates and recovery, 
whereas LQT2 mutation carriers have a long Tpe interval at the beginning of 
exercise and at the end of recovery at low heart rates. LQT3 mutation carriers 
exhibit prominent shortening of both QT and Tpe intervals in exercise stress tests. 
A small epinephrine bolus revealed disturbed repolarization, especially in LQT2 
mutation carriers, who developed prolonged Tpe intervals. A higher epinephrine 
bolus caused abnormal T waves with a different T wave profile in LQTS mutation 
carriers compared to healthy controls (p=0.027). These effects were seen in LQT3 
as well, a group that may easily escape other provocative tests. In the cetirizine test, 
the QT and Tpe intervals were not prolonged in LQTS mutation carriers or in 
healthy controls, even at supra-therapeutic doses. The Tpe interval was slightly 
shortened in the LQT1 group. 
 
LQTS mutation carriers with normal or non-diagnostic QT interval duration exhibit 
abnormalities during exercise stress tests and epinephrine provocation. These 
subtype-specific findings help to diagnose silent LQTS mutation carriers and to 
guide subtype-specific treatments. The Tpe interval, which signifies the 
repolarization process, seems to be a sensitive marker of disturbed repolarization 
along with the QT interval, which signifies the end of repolarization. The method is 
useful in studying compounds that are suspected to affect repolarization. Cetirizine 
did not adversely alter ventricular repolarization and would not be pro-arrhythmic 
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APD action potential duration 
bpm beats per minute 
BSPM body surface potential mapping 
ECG electrocardiogram 
HR heart rate 
LQT1 subtype 1 of long QT syndrome 
LQT2 subtype 2 of long QT syndrome 
LQT3 subtype 3 of long QT syndrome 
LQTS long QT Syndrome 
QTc heart rate corrected QT end interval, by Bazett’s formula 
QTfc heart rate corrected QT end interval, by Fridericia’s formula 
QT peak the interval from the onset of the Q wave to the peak of the T wave, QT 
apex interval 
QT end the interval from the onset of the Q wave to the end of the T wave, QT 
interval 
TdP torsade de pointes ventricular tachycardia 
TDR transmural dispersion of repolarization 
















Congenital long QT syndrome (LQTS) is a familial disorder caused by mutations in 
genes that encode cardiac ion-channel proteins. Defects in these ion channels lead to 
impaired ventricular repolarization, which may provoke a polymorphic ventricular 
tachycardia called torsade de pointes (TdP) and lead to syncope –and occasionally- to 
ventricular fibrillation and sudden cardiac death. The same features characterize 
acquired LQTS, in which ventricular repolarization is impaired by, for example, drugs 
or other ion channel blocking agents. 
 
 Several subtypes of congenital LQTS have been described, but the three most 
common (LQT1, LQT2, and LQT3) constitute 95% of the cases (Zareba 2008). 
Although the disorder is characterized by QT interval prolongation in surface 
electrocardiograms, in 25-35% of carriers the resting QT interval is normal or only 
slightly lengthened (Priori et al. 1999, Johnson and Ackerman 2009). These silent 
carriers are also at risk of developing TdP tachycardia, and sudden death (Schwarz 
2006), especially when exposed to agents that may further impair ventricular 
repolarization.  
 
Genetic testing has become an important tool for diagnosing carriers of congenital 
LQTS mutations. Still, a large proportion of carriers escape molecular diagnosis. 
Additional tests that would reveal abnormal ventricular repolarization are needed, 
especially for recognizing LQTS subtypes, and for helping in choosing subtype specific 










2. REVIEW OF THE LITERATURE 
 
2.1. Action potential  
  
Electrical signalling in cells involves the passage of ions though ionic channels. The 
major charge carriers are Na+, K+, Ca2+ and Cl- ions. Each ion moves primarily through 
its own ion-specific channel. Their movements across the cell membrane generate 
excitation, which spreads from one cell to the next through gap junctions.   
 
 Cardiac action potential (AP) consists of five phases. These phases are a result of 
passive ion fluxes moving according to electrochemical gradients established by active 
ion pumps and exchange mechanisms. The intracellular resting potential during diastole 
is -50 to -95 mV. Phase 0 – rapid depolarization - evokes an action potential. It is 
caused by sudden increase in membrane conductance to Na+ ions (the INa channels). 
Phase 1 – early rapid repolarization - is caused by inactivation of the INa channels and 
concomitant activation of several transient outward K+ currents (Ito). Phase 2 – plateau 
– is maintained by competition between the outward movement of K+ through rapid (IKr) 
and slow (IKs) outward rectifying channels, the inflow of Ca2+ ions through open L-type 
Ca+ channels, and the inflow of Na+ by Na+/Ca+ exchanger. Phase 3 – final rapid 
repolarization - proceeds owing to inactivation of ICa.L channels and activation of 
repolarizing K+ currents (IKs, IKr) and inwardly rectifying K+ currents (IK1, Ik.Ach). All of 
this causes an increase in the movement of positive charges out of the cell and the 
membrane potential shifts to the resting potential.  Phase 4 – resting membrane 
potential – the negative intracellular potential is maintained before the next AP (Rubart 
and Zipes 2005). Phase 0 produces cardiac depolarization, and repolarization consists of 
phases 1 to 3.    
 
2.1.1. Action potential duration 
 
Myocardial electrical activity is initiated in the pacemaker cells in the sinoatrial node, 
then propagated though the atria to the atrioventricular node and, after a brief pause in 
the conducting Purkinje fibers, further into the myocardium. Each of these regions has 
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slightly different AP waveforms, because of differences in ion channel expression levels 
(Nerbonne and Kass 2005).  
 
 Prolongation of action potential duration (APD) can be achieved by a reduction of 
the outward currents, particularly the IKs or IKr potassium currents and/or enhancement 
of the inward currents (INa) during phases 2 and 3 of the action potential (Ackerman and 
Clapham 1997). The different APD lengths between layers of cells or areas of the heart 
is named dispersion of repolarization. This is studied by recording the signals of 
monophasic action potential (MAP) in a variety of experimental mammalian heart 
models and in intact animal hearts (Killeen et al. 2008). An experimental model based 
on arterially perfused, left ventricular free-wall wedge preparations suggests that, 
among the three prominent cell-types within the ventricular wall, the APD is briefest in 
epicardial cells, and longest in mid-myocardial M cells, and of middle duration in 
endocardial cells. Thus, the difference in APD between the epicardium and the M 
region defines the transmural dispersion of repolarization (TDR) (Yan et al. 1998). 
Although some have shown differences in IKs density between the right and the left 
ventricle contributing to interventricular dispersion (Volders et al. 1999), others have 
claimed that it is increased transmural rather than interventricular repolarization that 
generates the vulnerable window for the development of arrhythmias (Milberg et al. 
2005). On the other hand, recently the TDR from transseptal region was shown to be 
markedly long compared to TDR from the left ventricular free wall, highlighting the 
non-homogenous nature of ventricular repolarization (Sicouri et al. 2010). 
 
 It has been suggested that IKs is the dominant determinant of the physiological heart 
rate dependent shortening of APD. With increasing heart rate IKs channels remain open, 
leading to faster rate of repolarization (Tamargo et al. 2004). APD of the ventricle 
shortens with adrenergic stimulation. M cells are distinguished by the ability of their AP 
to be more prolonged than the AP of epicardial and endocardial cells in response to β-
adrenergic stimulation. This may be due to the relative scarcity of IKs currents in M cells 




2.1.2. Torsade de pointes  
 
Afterdepolarizations are oscillations of the transmembrane potential that are capable of 
generating a premature AP (a triggered beat). Afterdepolarizations may occur before 
(early afterdepolarizations; EADs) or after (delayed afterdepolarizations; DADs) full 
repolarization. EADs occur during the course of an AP, and their appearance strongly 
depends on the AP duration and dispersion of repolarization within the ventricular wall 
(Yan et al. 2001). EAD can induce a propagated response and an extra beat, potentially 
launching torsade de pointes (TdP) ventricular tachycardia. Usually a “short-long-short” 
sequence, or “pause dependent” phenomenon (oscillations in preceding RR intervals), is 
seen before the initiating extra beat (Viswanathan and Rudy 1999, Vos et al. 2000, 
Noda et al. 2004). 
 
 In re-entry, anatomically defined separate pathways (anatomical re-entry) or a group 
of fibers (functional re-entry) serve as a link to re-excite areas that were just discharged. 
El-Sherif et al. presented evidence that EAD-induced activity initiates TdP, but the 
arrhythmia is maintained by a re-entrant mechanism (El-Sherif et al. 1996). 
Heterogeneous ventricular repolarization (dispersion of repolarization) may serve as 
substrate for re-entry under various conditions (Patel et al. 2009), and decreasing 
transmural dispersion of repolarization suppresses TdP (Shimizu and Antzelevitch 
1997, Shimizu and Antzelevitch 1998, Shimizu and Antzelevitch 2000b). It has been 
suggested that mid-myocardial M cells play an important role in the genesis of TdP, 
because EADs may develop preferentially in M cells (Viswanathan and Rudy 1999) and 
M-cell zones may produce the discrete refractory borders responsible for the conduction 
block that gives rise to re-entry (Akar et al. 2002). A Dutch group has proposed 
interventricular dispersion of repolarization as a factor that predisposes to TdP 







2.2. Ventricular repolarization in electrocardiogram 
 
2.2.1. QT interval 
 
The QT interval represents the duration from the onset of depolarization to the 
completion of repolarization. In ECG, it is defined as the interval from the earliest onset 
of the QRS complex to the end of the T wave (Rautaharju et al. 2009). The onset of the 
QRS complex is usually easily identified, but the end of T wave may be more difficult 
to determine. In the most frequently used method, a tangent line to the steepest part of 
the descending limb of the T wave is drawn; the intersection between this and the 
isoelectric line is defined as the end of T wave (Lepechkin and Surawitch 1952). The 
shape of the T wave is variable. Problems arise when the T wave is complex, or when 
the T and U waves cannot be distinguished. QT interval length has been shown in 
several studies to be an independent risk factor for arrhythmias in LQTS patients (Moss 
et al. 1991, Priori et al. 2003, Sauer et al. 2007). 
 
 Traditionally, lead II of a standard 12-lead ECG has been used for QT interval 
measurement, because in this lead the vectors of repolarization usually result in a long 
single wave. This lead has been recommended for measuring the QT interval in LQTS 
patients, and when not measureable, then a left precordial lead (preferable V5) (Mönnig 
et al. 2006). The maximum QT interval duration, however, frequently occurs in 
different leads. If one wishes to report the longest QT interval duration, each lead 
should be measured separately. This is usually not possible in large studies. Cowan et 
al. have stated that leads V2 and V3 provided the closest approximation to the 
maximum QT interval and therefore recommended that they be used for the 
measurement (Cowan et al. 1988). The average, or median, QT interval duration as 
measured by a number of different leads has, for simple mathematical reasons, much 
superior stability (Camm at al. 2004). In general, it is not recommended to measure a 
single beat; at least three separate measurements over time should be considered (Malik 
et al. 2002, Hinterseer et al. 2009). 
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 QT interval is strongly correlated to heart rate. It adapts to heart rate changes, which 
makes QT intervals recorded at different heart rates difficult to compare. To allow such 
a comparison, several formulas have been proposed. Most of these formulas are 
expressed as QTc = QT/RRα, where RR is the preceding cycle length in seconds. The 
most used are Bazett’s square-root formula where α is 0.5 (Bazett 1920) and 
Fridericia’s cubic-root formula where α is 0.33 (Fridericia 1920). However, the 
QT/heart-rate relation exhibits high inter-subject variability, and therefore the use of 
general heart-rate correction formulas may lead to inaccurate conclusions (Malik et al. 
2002). If heart-rate adjusting formulas are used, the representative ECG trace should be 
selected carefully since general heart-rate correction formulas can only be used for 
approximate clinical assessments over a narrow band of resting heart rates (Malik et al. 
2002, Napolitano et al. 2006) and the QT interval does not immediately adapt to rapid 
heart rate changes (Lau et al. 1988, Toivonen et al. 1997). 
 
 In repeated studies, e.g. in examining drug-induced QT interval changes, the 
variability of QT interval measurements over time should be taken into account (Sarapa 
et al. 2004). QT interval lengths also vary in patients with congenital LQTS. In serial 
ECG measurements of 375 paediatric LQTS patients, Goldenberg et al demonstrated 
considerable variability in QTc interval measures, the mean ± SD difference between 
minimum and maximum QTc values being 47 ± 40 ms. This highlights the need for 
serial ECG measures over time, especially in risk stratification (Goldenberg et al. 2006). 
In studies involving drug effects, it has been proposed that the maximum change from 
baseline should be reported. It is difficult to determine, however, whether the value 
obtained is a result of the drug intervention, the inherent variability of the QT interval 
over time, or of other confounding factors such as circadian changes. The QT interval 
has been shown to be approximately 20 ms longer during sleep (Bexton et al. 1986, 
Viitasalo and Karjalainen 1992). The U.S. Food and Drug Administration (FDA) 
suggests that ∆QT c intervals between 30-60 ms are likely to represent drug effects, 
while changes of greater than 60 ms should raise concern about a potential 




2.2.2. Dispersion of repolarization 
 
In 1990, the interlead difference in QT interval duration, termed “QT dispersion”, was 
proposed as an index of the spatial dispersion of ventricular repolarization (Day et al. 
1990). This is calculated simply by the difference between maximum and minimum QT 
intervals in a 12 –lead ECG. Later, this concept has been criticised by several studies. It 
seems that it does not reflect in a quantifiable way the heterogeneity of ventricular 
recovery times, and the methodology of the measurement is questionable. The 
measurement is poorly reproducible, and there are no reference values (Gang et al. 
1998, Malik and Batchvarov 2000, Liang et al. 2005). It has not been adequately 
validated as a risk indicator of proarrhythmia and therefore is not recommended as a 
parameter in assessing drug-induced alteration in ventricular repolarization (Haverkamp 
et al. 2000, Zareba 2007). Probably only very extreme values (e.g. > 100 ms) are of 
clinical significance (Priori et al. 1994, Malik and Batchvarov 2000, Dabrowski et al. 
2000). 
 
 Since the concept of M cells and TDR were introduced by Antzelevitch and co-
workers, there has been debate about its equivalent on electrocardiogram. In an 
experimental model, the TDR could be estimated from the ECG as the interval between 
the peak and the end of the T wave (Yan and Antzelevitch 1998, Shimizu and 
Antzelevitch 1998). Later, prolonged Tpe interval has been shown to be an index of 
arrhythmias. Tpe intervals were prolonged in a heterogeneous group of patients who 
had suffered ventricular arrhythmias (Watanabe et al. 2004), and the dynamic behaviour 
of Tpe intervals has been shown in ambulatory electrocardiographic recordings in 
LQTS patients (Viitasalo et al. 2002a).  
 
 Recent studies with animal models suggest, however, that Tpe intervals do not 
correlate with transmural dispersion of repolarization, but are rather an index of the total 
dispersion of repolarization (Opthof et al. 2007). Although the genesis of the Tpe 
interval still remains controversial, it has been shown to be a predictor of arrhythmias 
under a variety of clinical conditions (Patel et al. 2009).  
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2.2.3. Morphology of T waves  
 
Experimental models have provided evidence for a cellular basis for the T wave. The 
opposing voltage gradients between three myocardial cell -types (epi-, M-, and 
endocardial cells) have been shown to contribute to the deflection of the T wave in 
ECG. The end of repolarization of epicardial cells coincides with the peak of the T 
wave, and that of the M cells coincides with the end of T wave. The interplay between 
these opposite regions determines the height of the T wave and the degree to which the 
ascending or descending limb of T wave is interrupted, leading to bifurcated or notched 
appearance. The so-called T-U complex would then actually be an interrupted T wave, 
because the forces that give rise to U wave appear no different than those responsible 
for the T wave (Yan and Antzelevitch 1998). Notching of the T wave may be difficult to 
discriminate from a U wave, and it is suggested that the interval between a monophasic 
T wave and the U wave usually exceeds 150 ms at heart rates of 50 to 100 bpm 
(Lepechkin and Surawitcz 1957, Lehmann et al. 1994). 
 
 A number of descriptive terms are used for T waves, including peaked, flat, biphasic, 
bifid, asymmetrical and inverted. In study by Lehmann et al., three configurations of 
bifid T waves were designated and graded depending on the place and height of T wave 
protuberances (just beyond the peak or on the descending limb of the T wave) 
(Lehmann et al. 1994).  
 
 T wave alternans – beat-to-beat alternation of the morphology, amplitude and/or 
polarity of the T wave – has also been explained as an alternation in the M-cell APD 
(Shimizu and Antzelevitch 1999) indicating instability of repolarization (Rautaharju et 
al. 2009). Catecholamine-provoked microvoltage T -wave alternans was discovered at 
low heart rates in genotyped LQTS patients, but it failed to identify high-risk patients 






2.3. Congenital long QT syndrome 
 
In 1957 Jervell and Lange-Nielsen described a syndrome with prolonged QT intervals 
and congenital deafness, and in the early 1960s Romano and Ward independently 
described a similar disease with normal hearing. Thus, the Romano-Ward (RW) 
syndrome is an autosomal dominant disorder without congenital deafness while Jervell-
Lange-Nielsen (JLN) syndrome has been viewed as an autosomal recessive disease with 
congenital deafness. Since those days, it has been learned that the congenital LQTS is a 
genetic cardiac chanellopathy characterized by delayed ventricular repolarization, which 
exposes the affected to TdP ventricular tachycardia, possibly leading to syncope and 
sudden cardiac death (Moss and Robinson 1992, Schwarz et al. 1993, Camm et al. 
2000, Chiang and Roden 2000).  
 
 In 1995 and 1996, the three main genes for LQTS were identified. The LQT1 form 
involves mutations on the KCNQ1 (previously KvLQT1) gene, which encodes the slow 
delayed rectifier potassium repolarization channel, resulting in a reduction in IKs 
current; the LQT2 form involves mutations on the KCNH2 (HERG) gene, which 
encodes the rapid delayed rectifier potassium repolarization channel, resulting in a 
reduction in IKr current; and the LQT3 form involves mutations on SCN5A, the cardiac 
sodium channel gene, resulting in an increase in late INa current.  LQT1 and LQT2 
account for about 90% of positively genotyped LQTS cases, whereas LQT3 probably 
accounts for 5-8%. In a North American/European population, LQT1 constituted 42%, 
LQT2 45% and LQT3 8% of LQTS cases, whereas in Finland the corresponding figures 
were 71%, 23% and 6% (Splawski et al. 2000, Fodstad et al. 2004). As of today, 12 
LQTS genes have been identified, the remaining types being extremely rare (Schwarz 
2006, Ruan et al. 2008, Zareba and Cygankiewicz 2008). The prevalence of congenital 







2.3.1. Diagnosing LQTS 
 
Until now, genetic testing has yielded from research laboratories to commercially 
available. Among patients with definitive clinical evidence of LQTS, the portion 
diagnosed by genetic testing is about 75% (Tester et al. 2006). In Finland, two KCNQ1 
and two HERG mutations account for 73% of the Finnish LQTS cases (Fodstad et al. 
2004). As many patients still escape molecular diagnosis, genetic testing and clinical 
evaluation should be combined in the diagnosis and management of LQTS (Schwarz 
2006, Lehnart et al. 2007). 
 
 Clinical diagnostic criteria were first proposed in 1985, and were updated in 1993 
(Schwarz et al. 1993). The main revision concerned QT interval length. Merri et al. had 
discovered that, among healthy subjects average QTc values were significantly longer in 
women than in men (Merri et al. 1989). Vincent et al. confirmed the sex difference 
among LQTS carriers and described a large overlap of QTc values between carriers and 
non-carriers of LQTS. The highest overall accuracy for the diagnosis of gene-carrier 
status occurred at QTc ≥ 460 ms, yet 9% of male LQTS gene carriers had QTc values 
<440 ms (Vincent et al. 1992). These findings emphasized the limitations of resting QTc 
interval measurements for LQTS diagnosis and highlighted the need for additional 
criteria. See Table 1 for details. 
 
 The typical cases –syncope or cardiac arrest, often during physical or emotional 
stress, and QT interval prolongation on the ECG- present no diagnostic difficulty. 
However, borderline cases are more complex (Moss et al. 1985, Schwarz et al. 1993, 
Schwarz 2006). Because LQTS may appear with a low penetrance, the family members 
considered to be normal may be silent mutation carriers and unexpectedly at risk of 
developing TdP, especially if exposed to either cardiac or non-cardiac potassium 






Table 1. 1993 LQTS diagnostic criteria  
 
  Points 
ECG findingsa  
A. QTc b                        
     ≥ 480 ms       3 
     460-470 ms       2 
     450 ms (in males)       1 
B. Torsade de pointesc       2 
C. T wave alternans       1 
D. Notched T wave in three limb leads       1 
E. Low heart rate for aged       0.5 
Clinical history  
A. Syncopec  
     With stress       2 
     Without stress       1 
B. Congenital deafness       0.5 
Family history (either A or B)  
A. Family member with definite LQTSe       1 
B. Unexplained sudden cardiac death below age 30 among immediate 
family members 
      0.5 
 
aIn the absence of medications or disorders known to affect these electrocardiographic 
features 
bQTc calculated by Bazett’s formula. 
cMutually exclusive 
dResting heart rate below the second percentile for age. 
eDefinite LQTS is defined by an LQTS score ≥4. 
 
Zero or one point indicate a low probability of LQTS, 2 or 3 points an intermediate and 
4 or more points a high probability of LQTS.  
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 Although the disorder is characterized by QT interval prolongation, in nearly 40% of 
LQTS patients, resting QTc  interval is normal or only slightly lengthened. In other 
words, the average QTc penetrance – i.e. those individuals presenting a QTc longer than 
440 ms for men and 460 ms for women- has been shown to be 60% among genetically 
affected family members. Patients with LQT2 and LQT3 present higher QTc penetrance 
(70-79%) compared to LQT1 (55%)(Vincent et al. 1992, Priori et al. 1999, Priori et al. 
2003, Napolitano et al. 2005). On the other hand, fully 15% of the general population 
may have a QTc in the borderline range, so there is substantial overlap in the 
distribution of QTc between otherwise healthy subjects and patients with genetically 
confirmed LQTS (Johnson and Ackerman 2009). 
 
 Silent mutation carriers are potentially at risk for sudden cardiac death (Schwarz 
2006, Priori et al. 2003). Many attempts have been made to facilitate the diagnosis of 
LQTS. The most useful tools for diagnosing LQTS as well as the main subgroups are 
clinical presentation, special ECG features, exercise stress tests, ambulatory 
electrocardiographic recordings, and epinephrine infusion tests. 
 
Clinical presentation  
The conditions (triggers) associated with cardiac events suggest certain LQTS subtypes. 
In LQT1, most events occur during exercise and only a minority during rest or sleep. 
Swimming as a trigger is particularly frequent in LQT1 patients. In contrast, in LQT3 
patients only a minority of the events occur during exercise, and most occur during rest 
or sleep. LQT2 patients have an intermediate pattern with most of the events occurring 
during emotional stress. Auditory stimuli occur as a specific trigger in LQT2 (Schwarz 
et al. 2001).   
   
Typical ST-T –wave patterns 
Already in 1995, Moss et al. described LQTS-subtype-specific T wave patterns (Moss 
et al. 1995). In a study by Zhang et al., four typical LQT1 patterns (infantile, broad -
based T wave, normal -appearing, and late –onset normal -appearing); four LQT2 
patterns (4 subtypes of bifid T –waves); and two LQT3 patterns (late –onset 
peaked/biphasic T wave, and asymmetrical peaked T –wave) were described. These 
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patterns were present in 88% of LQT1 and LQT2 carriers and in 65% of LQT3 carriers. 
Family-grouped ECG analysis improved genotype identification accuracy. In that study, 
however, only 6/387 patients (1.6%) had a normal ST-T-wave pattern with a normal 
QTc interval (Zhang et al. 2000). 
 
Exercise stress test 
The LQT1 form of LQTS is characterized by an inadequate sinus rate response to 
exercise and an exacerbation of QT interval prolongation after physical effort. In 
contrast, in LQT2 the QT interval shortens more than in LQT1 and the sinus node 
response is normal. LQT3 patients shorten their QT intervals in response to heart rate 
even more than LQT2 patients (Vincent et al. 1991, Schwarz et al. 1995, Swan et al. 
1999). Takenaka et al. studied Tpe intervals during exercise tests in LQT1 and LQT2 
patients. They reported increased heart rate adjusted Tpe –intervals (Tpec) in LQT1, but 
not LQT2 patients. The majority of patients were symptomatic with markedly 
prolonged QT intervals (Takenaka et al. 2003). 
 
Ambulatory electrocardiographic recordings 
Holter monitoring may reveal periods of profound bradycardia, runs of TdP, transient 
QTc prolongation, or episodes of T wave alternation that may help in revealing the 
syndrome (Moss and Robinson 1992). Measures of QT interval dynamics and Tpe 
intervals may help in differentiating between LQT1, LQT2 and healthy subjects, since, 
LQT1 patients exhibit increasing Tpe intervals at elevated heart rates, whereas LQT2 
patients increase their Tpe intervals at a much wider range of heart rates (Nemec et al. 
2004, Viitasalo et al. 2002a, Viitasalo et al. 2002b). 
 
Epinephrine infusions 
From the clinical presentation of the syndrome, exogenous adrenergic stimulation might 
be expected to prolong QT intervals in affected subjects. In an experimental LQT1 
model, β -adrenergic stimulation prolonged the QT and APD of mid-myocardial M 
cells, but abbreviated the same in epi- and endocardial myocytes, causing a persistent 
increase in TDR. In a LQT2 model, adrenergic stimulation initially prolonged and then 
reduced the APD of M cells, but always reduced the APD of epicardial cells, thus 
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transiently increasing TDR. In a LQT3 model, the APD of all three cell–types was 
reduced, causing a persistent decrease in TDR (Shimizu and Antzelevitch 1998, 
Shimizu and Antzelevitch 2000).  
 
 Two protocols with epinephrine infusion and adequate sensitivity and specificity 
values have been published: the Shimizu protocol and the Mayo protocol. In Shimizu, 
the test begins with an epinephrine bolus of 0.1 µg/kg followed by immediate infusion 
of 0.1 µg/kg/min. Shimizu et al have reported a lengthening of heart rate adjusted QT 
and Tpe intervals, with more pronounced effects in the LQT1 group compared to LQT2. 
The protocol may distinguish latent LQT1 mutation carriers, and also help to 
distinguish LQT2 patients with transient QTc prolongation during the peak epinephrine– 
effect (Noda et al. 2002, Shimizu et al. 2003, Shimizu et al. 2004). A larger increase in 
spatial dispersion of repolarization (measured as time between the longest and shortest 
QTc intervals) in LQT1 patients compared to LQT2 patients has been reported. In the 
same study, there was no difference between LQT1 and LQT2 in terms of spatial 
dispersion of heart rate adjusted QT peak interval (Tanabe et al. 2001). 
 
 In the Mayo protocol, an epinephrine infusion without a bolus is used, and QT 
intervals are not adjusted for heart rate. A low-dose epinephrine infusion (0.05 
µg/kg/min) caused marked prolongation in absolute QT interval in LQT1 patients and 
shortening in both the LQT2 and the LQT3 group. At higher doses, infusion caused 
paradoxical QT prolongation in some controls. The QTc interval showed no 
discriminative value (Ackerman et al. 2002, Vyas and Ackerman 2006, Vyas et al. 
2006). 
 
2.3.2. Management of LQTS 
 
β -blockers have remained the first choice of therapy for LQTS irrespective of the 
genotype, although their benefit in LQT3 has not been demonstrated (Lehnart et al. 
2007, Patel and Antzelevitch 2008). β -blockers have been shown to provide significant 
reduction in event rates in LQT1 and LQT2 patients (Moss et al. 2000, Sauer et al. 
2007, Vincent et al. 2009), whereas there was no evident effect on events in LQT3 
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patients (Moss et al. 2000). The rate-adjusted QTc intervals at rest were not changed 
(Moss et al. 2000), but abrupt lengthening of QT and Tpe intervals at elevated heart 
rates were decreased in LQT1 patients (Viitasalo et al. 2006). The limitations of β -
blocker treatment are due to side-effects, which may result in noncompliance (Patel and 
Antzelevitch 2008, Vincent et al. 2009). 
 
 Sodium channel blockade represents a rational approach as gene-specific therapy for 
LQT3, since mutations causing LQT3 induce excess sodium to enter into the myocytes. 
Preliminary studies have shown that mexiletine effectively shortens the QT interval in 
LQT3 (Schwarz et al. 1995), but there is no long-term data that mexiletine improves 
survival in LQT3 (Napolitano et al. 2006). Another sodium channel blockade, 
flecainide, should be used with caution in LQT3 patients since it induced an ST–
segment elevation resembling Brugada syndrome in about 50% of cases in unselected 
LQT3 patients (Napolitano et al. 2006). 
 
 Oral potassium supplements are effective in reducing repolarization abnormalities in 
LQT2, but no data demonstrate that they can also reduce the risk of cardiac events 
(Ruan et al. 2008, Napolitano et al. 2006, Patel and Antzelevitch 2008). LQT2 patients 
are vulnerable when the potassium level is low, so maintaining adequate levels is 
advised (Schwarz 2006).  
 
 Implantable cardioverter-defibrillators (ICD) are indicated for patients who are at 
high risk for ventricular arrhythmias, who have recurrent arrhythmogenic syncope or 
who have ventricular fibrillation during adequate β -blocker therapy (Priori et al. 2002, 
Lehnart et al. 2007, Hayes and Zipes 2005, Zareba and Cybankiewicz 2008); as well as 
for primary prevention in patients with markedly prolonged QT intervals (QTc >550 ms) 
and signs of high electrical instability (Schwarz et al. 2010). Since LQT3 patients are at 
highest risk of TdP when the heart rate is slow, pacemaker therapy is thought to be 
most beneficial for them. Pause-dependent TdP is most prevalent in LQT2, and hence 
pacemaker therapy may also be therapeutic for this group by suppressing pauses (Patel 
and Antzelevitch 2008). For patients who develop severe bradycardia during β -blocker 
therapy, concomitant pacemaker therapy is indicated (Chiang and Roden 2000).    
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 Although left cardiac sympathetic denervation is very effective in reducing the risk 
of repeated events in LQTS, this treatment should be limited to a subset of the patients 
who continue to experience cardiac events despite β -blocker treatment and 
interventional management in terms of pacemakers and defibrillators (Patel and 
Antzelevitc 2008, Zareba and Cygankiewicz 2008, Schwarz 2006). 
 
 All LQTS patients (symptomatic and asymptomatic) should be provided with a list of 
the potentially harmful drugs that may affect ventricular repolarization. There is a 
consensus that individuals with LQTS should not be considered eligible to perform 
competitive sports, except low -dynamic and low-static sports (golf, billiards, bowling 
etc.). The recommendations for recreational physical activity are much less clear; high-
intensity sports are “not advised” or “discouraged”, whereas low-intensity activities are 
“probably permitted”. The recommendations can be individualized based on genotype: 
LQT1 patients should avoid physical stress; in LQT2, limits can be more flexible; and 
in LQT3, recreational activity does not have to be restricted at all. Based on the 
arrhythmia triggers, swimming and diving are contraindicated in LQT1 patients (Priori 
et al. 2002, Napolitano et al. 2006, Schwarz 2006, Kapetanopoulos et al. 2006).     
 
2.3.3. Risk stratification 
 
Contrary to previous knowledge, LQTS appears to carry a high risk of life-threatening 
cardiac events throughout adulthood. This risk is associated with clinical and genetic 
factors. Genotype is an independent risk factor: patients with LQT2 mutations are at a 
greater risk for cardiac events than patients with LQT1 or LQT3. However, the lethality 
of cardiac events is highest in LQT3. Women have a higher risk of cardiac events, as do 
patients who experienced their first event before the age of 18. Long QTc intervals (≥ 
470 ms) predisposes to arrhythmias; patients with borderline (440-469 ms) or normal 
(<440 ms) QTc are at lower risk (Priori et al. 2003, Zareba et al. 2003, Sauer et al. 2007, 




2.4. Acquired long QT syndrome 
 
2.4.1. Drug –induced long QT 
 
Syncope related to the use of quinidine was described already in the 1920s, but the 
cause of syncope was not understood until the 1960s. The QT prolonging effect of the 
drug leads to TdP tachycardia. Non-cardiac drugs may also have this property, and 
assessing the QT prolonging effects of compounds is currently a major concern in drug 
development. The risk of possible repolarization prolongation must be weighed against 
the possible benefits. If a drug is effective in treating oncological disorders, then some 
degree of QT prolongation may be acceptable. On the other hand, if the drug is 
marketed to treat allergic rhinitis in otherwise healthy people, then even minor QT 
prolongation may be unacceptable (Haverkamp et al. 2000, Heist and Ruskin 2010).  
 
 Drug-induced QT prolongation is a complicated phenomenon related not only to the 
ion channel blocking properties of a given drug but also to drug-drug interactions and a 
variety of patient- specific factors (Heist and Ruskin 2010). Most clinically relevant ion-
channel blocking occurs via inhibition of IKr potassium current, encoded by HERG. 
Both direct block of the HERG channel and disruption of HERG trafficking to the 
cardiac cell membrane have been described (Roy et al. 1996, Taglialatela et al. 1998, 
Heist and Ruskin 2010). Concomitant use of several drugs that share the same 
metabolic pathway, such as the major cytochrome P450 (CYP3A4) enzyme system, is 
likely to augment individual drug levels (Honig et al. 1992, Honig et al. 1993, Zareba 
2007). 
 
 Most patients subjected to drug-induced TdP have at least one recognizable risk 
factor (Table 2). Women account for 70% of drug-induced LQTS cases (Makkar et al. 
1993). Metabolic factors like low magnesium (Kay et al. 1983), low calcium (Akiyama 
et al. 1989) and especially low extracellular potassium (Kay et al. 1983, Yang and 
Roden 1996) predispose to TdP. Spontaneous or drug-induced bradycardia also increase 
the risk (Topilski et al. 2007). In cohorts of acquired LQTS patients, 10-15% carry 
variants of the known LQTS genes (Yang et al. 2002, Paulussen et al. 2004). Of 
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disease–causing mutations, the most common occurs in KCNQ1 (LQT1), where a 
subclinical loss of IKs function may become apparent when superimposed to IKr block 
(Roden 2006). Common variants (polymorphism) within the human genome may also 
impair repolarization reserves and predispose to drug-induced TdP (Splawski et al. 
2002, Kannankeril 2005, Marjamaa et al. 2008).    
 
 Most cases of drug-induced TdP occur in the context of a substantial prolongation of 
the QT interval. However, QT interval alone seems to be relatively poor predictor of 
arrhythmic risk because not all drugs that prolong QT intervals also induce TdP (van 
Opstal et al. 2001, Heist and Ruskin 2010). In experimental models, drugs that cause 
homogenous prolongation of APD within the three predominant myocardial cell types 
do not initiate TdP, whereas drugs that cause heterogeneous prolonging of APD 
(increase TDR) frequently do (Weissenburger et al. 1999, Antzelevitch 2004).   
 
 








Congestive heart failure (prolonged APD) 
Left ventricular hypertrophy (prolonged APD) 
High drug concentration (overdose or impaired elimination) 
Concealed congenital LQTS 




2.4.1.1. Cardiac drugs 
 
The drugs that carry the greatest risk for QTc prolongation and TdP are class III 
antiarrhythmics (sotalol, ibutilide, dofetilide and azimilide), for which HERG inhibition 
and QTc prolongation are part of the therapeutic mechanism of action (Heist and Ruskin 
2010). Amiodarone, on the other hand, is rarely associated with TdP. This is possible 
because amiodarone causes homogenous APD lengthening by blocking several ion 
currents and suppressing EADs (van Opstal et al. 2001). In contrast, sotalol, which is a 
rather selective IKr current blocker, prolongs the QT interval and sometimes produces 
TdP (Funck-Breantano 1993, Hohnloser 1997). The effect is dose- and concentration 
dependent. 
 
 Quinidine, a class Ia antiarrhythmic, produces marked prolongation of APD in M 
cells at relatively low therapeutic concentrations. High concentrations cause 
prolongation of APD in epicardial and endocardial cells, but shortening in M cells by 
suppressing late INa current. Thus, low concentrations prolong TDR and cause TdP 
whereas high concentrations do not (Jenzer and Hagemeijer 1976).  
 
2.4.1.2. Non-cardiac drugs 
 
The main non-cardiac drugs that prolong the QT interval and are associated with TdP 
include certain psychiatric drugs (antipsychotics and antidepressants), antimicrobial 
drugs (macrolides and quinolones), and antihistamines (terfenadine and astemitzole) 
(Haverkamp et al. 2000). 
 
 Second-generation antihistamines were widely used in the 1980s because they lack 
the sedative properties displayed by first generation antihistamines. Soon, several 
reports about TdP after administration of terfenadine and astemitzole were published. 
These drugs were discovered to be potent HERG channel blockers, thus prolonging 
APD and the QT interval. Although the effect was evident mainly at supra-therapeutic 
concentrations (overdose or concomitant use of CYP3A4 blockers), these drugs were 
withdrawn from the market (Honig et al. 1992, Honig et al. 1993, Benton et al. 1996, 
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Ducic et al. 1997, Pratt et al. 1996). Another second-generation antihistamine, 
cetirizine, was shown to lack HERG blocking properties in experimental studies 
(Carmeliet 1998, Taglialatela et al. 1998) and to avoid the QT prolonging effects in 
healthy subjects (Sale et al. 1994). Thus, HERG block is not a class effect of second-
generation antihistamines. 
  
2.4.2. Other QT prolonging conditions 
 
QT interval is prolonged in many cardiac diseases, e.g. myocardial infarction, dilated 
cardiomyopathy, congestive heart failure and hypertrophic cardiomyopathy (Ahnve 
1985, Berger et al. 1997, Atiga et al. 2000). Bradycardia increases the amplitude of 
EADs and produces abnormal repolarization, thus increasing the risk of TdP 
(Brachmann et al. 1983). 
 
 Insulin secretion and glucose intolerance are independently associated with the QTc 
interval length, which may predict ventricular electrical instability in these diabetic 
patients (Dekker et al. 1996). Other metabolic causes are hypokalaemia, 
hypomagnesaemia, and hypocalcaemia (Curry et al. 1976, Loeb et al. 1968, Akiyama et 















3. AIMS OF THE STUDY 
 
The overall purpose of these studies was to improve the detection of long QT syndrome 
mutation carriers who have indeterminate phenotype.   
 
 First, a multichannel BSPM electrocardiogram with a computerized system was 
tested for repeatability and accuracy of QT interval analysis (Substudy I). In addition to 
the QT interval duration, T wave peak to T wave end intervals (Substudies I-III, V) and 
T wave shapes (Substudy IV) were studied. 
 
 In order to find differences in ventricular repolarization between LQTS mutation 
carriers and healthy subjects, the method was applied in interventions such as a physical 
exercise test (Substudy II) and an epinephrine injection test (Substudies III and IV). A 




















4. SUBJECTS AND METHODS 
 
4.1. Subjects  
 
A total of 81 subjects participated in the studies. We included 49 LQTS family 
members (27 females), all asymptomatic mutation carriers of KCNQ1, HERG or SCN5A 
genes. They were otherwise healthy and had normal or only marginally prolonged QT 
end intervals. No one had β -blocker therapy prior to or during the studies. Subjects 
with LQT1 (n=22) had four different KCNQ1 mutations (G589D, R366W, IVS7-2A, 
R518X), with LQT2 (n=17) four HERG mutations (del453C, L552S, R176W, G584S), 
and with LQT3 (n=10) four SCN5A mutations (V1667I, I239V, A691T, E1784K). In 
addition, 32 healthy volunteers (14 females) were studied. They had no history of 
syncope, or any clinical evidence of cardiovascular disease, and had normal baseline 
QT intervals. None took any regular medication during the studies. All participants 




4.2.1. Physical exercise stress test 
 
At the beginning of the test, ECG was recorded in supine position for 3 minutes. 
Thereafter an exercise stress test was performed using a bicycle ergometer. The initial 
load was set at 30 W, increased each minute by increments of 15 W for women and 20 
W for men until exhaustion. After cessation of exercise, subjects immediately lay down, 
and an ECG was recorded for 10-15 min (the recovery period). Blood pressure was 









4.2.2. Epinephrine test 
 
Subjects were lying on a bed in a quiet and dim room, in order to achieve restful and 
comfortable conditions. An antecubital vein was cannulated, and physiological saline 
solution infused. After an adequate period of relaxation, the test was started with a one-
minute ECG recording. A rapid bolus dose of epinephrine was administrated 
intravenously. Five doses (0.005 µg/kg, 0.01 µg/kg, 0.02 µg/kg, 0.04 µg/kg, and 0.1 
µg/kg) were given consecutively; however, no more than 10 µg was administered at a 
time. ECG recording was started at the moment of injection, and registered 
continuously for six minutes. A short pause was always observed before the next dose 
was given. Blood pressure was measured at 1, 2, 4 and 6 minutes after injection. 
Measurement was done non-invasively from standard position of the arm by using an 




4.2.3.1. Signal acquisition 
 
A body surface potential mapping (BSPM, BioSemi Mark-6) system was used for 
recording potentials from the anterior chest. The BSPM system utilizes 120 electrodes 
in 18 flexible plastic strips, and three limb leads with electrodes attached to the right 
and left shoulders and to the left hip area. Twelve pre-cordial leads located on the 
anterior chest were selected for the final analysis (Fig.1). These leads usually showed 
positive T waves, and were not notably disturbed while cycling. In the antihistamine 
study (Substudy V), a reduced layout with six pre-cordial leads was used. Recordings 
were stored on a computer disk.  
 
   
   
 




4.2.3.2. Analysis of electrocardiograms 
 
An automatic algorithm was applied to analyze the ECG data (Oikarinen et al. 1998). 
All selected channels were visualised simultaneously on the computer screen, and noisy 
channels were rejected. All 12 channels were included in the analysis of the resting 
data, whereas on average 9.4 channels were utilized for exercise test data analysis. In 
the antihistamine study, analyses were carried out utilizing signals of the six selected 
channels. Each ECG lead was first pre-processed by detecting the QRS complexes by 
an amplitude trigger, by determining the baseline, and creating a QRS template. Atrial 
and ventricular premature complexes were excluded. Each normal QRS-T deflection 
was replaced by an averaged QRS-T deflection comprised of the two previous and two 
following normal heartbeats, using a moving window. After pre-processing, the QRS 
onset was determined by going towards the QRS from the PR interval until a certain 
threshold limit was reached.  
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 The QT peak was determined as the peak of the parabola fitted to the highest 
amplitude change after the QRS. In cases of monophasic T waves, or at high heart rates, 
the QT end was defined as the intersection of the baseline with the steepest tangent after 
the QT peak. In cases of non-monophasic T waves, the second derivate was also used to 
detect discontinuities after the peak, and the U waves were excluded using the 
previously published guidelines (Lepechkin and Surawicz 1952). Bifid T waves 
exhibiting a time interval ≤  0.15 s between the first and second components were 
regarded as T waves. Otherwise, the second component was considered as a U wave 
(Lehman et al. 1994). The Tpe interval was defined as the QT peak interval subtracted 
from the QT end interval. All measurements were visually inspected, and clearly 
misinterpreted time points were excluded.  
 
4.2.3.3. Determination of the intervals 
 
After pre-processing, the values for the QT peak, QT end, and Tpe intervals for each 
heartbeat and lead were obtained. The mean values over the selected leads and intervals 
were calculated for each heartbeat. These beat-by-beat values were then averaged over 
certain time periods.  
 
 At rest before the exercise test, the QT peak, QT end, and Tpe intervals were 
averaged for a 30 second period at the end of the recording. Resting QT end intervals 
were corrected for heart rate by using Bazett’s and/or Fridericia’s formulas (Bazett 
1920, Fridericia 1920; QTc and QTfc, respectively). Intervals were analysed at specified 
heart rates from 90 to 150 bpm during workload, and from 140 to 100 bpm during 
recovery by steps of 10 beats/min, allowing a tolerance of ±2 bpm. Averages of 10-20 
consecutive heartbeats were used. Intervals were then compared without heart- rate 
correction formulas. QT interval/heart-rate (QT/HR) and Tpe interval/heart-rate 
(Tpe/HR) slopes were also calculated during exercise and recovery for each group. To 
examine whether QT intervals differed between channels, the intervals were averaged in 
each lead separately for the last 30 s at rest, and the standard deviation (SD) of the 12 
leads was then calculated.    
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 In the epinephrine test, time intervals were determined as an average from three 
consecutive beats at rest. After administration of epinephrine, QT end and Tpe intervals 
were examined at their longest, and QT peak at its shortest. The interlead variation was 
studied by calculating SD of the channels. At rest and at the highest HR, the QT end 
interval was also corrected for HR by Bazett’s formula. In cases of remarkable T wave 
changes, when interval values from all twelve channels could not be obtained, T wave 
morphology was determined. T wave patterns were classified as follows: 1) Normal –
appearing, when epinephrine did not cause any remarkable changes despite slight 
flattening of the T wave; 2) Biphasic, consisting of positive and negative oscillations, 
followed by a slight third positive component; 3) Inverted, in which the T wave lay 
completely under the baseline with only minor or no positive oscillations in the vicinity; 
4) Obvious bifid; 5) Combined pattern, with a biphasic or inverted component in some, 
and a bifid component in others of the 12 pre-cordial channels. The T wave pattern was 
evaluated at the time of its maximal change. 
 
4.2.4. Statistical analyses 
 
Continuous values are presented as mean ± SD. Parametric tests were used for data 
having a normal distribution, otherwise nonparametric tests were used. Student’s paired 
t –test was used for intra-individual comparison. Differences between groups were 
assessed by one-way analysis of variance and by Scheffe’s test, an independent sample 
T test, and with the Mann-Whitney U test when appropriate. For dichotomous variables, 
chi-square test was used. A two-tailed P value <0.05 was considered statistically 
significant. The repeatability of the measurements during exercise tests was assessed by 
coefficient of variation (CV) (Bland and Altman 1996a,b). CV was determined by 
analysis of variance, calculated as the square root of the mean square of within-subject 
variability divided by the mean of each variable. CV values are expressed as percents. 
Statistical analyses were carried out with the commercial software SPSS for Windows 





4.3. Study designs 
 
4.3.1. Physical exercise stress tests  
 
We studied the reproducibility of QT interval measurements from several ECG leads by 
an automated algorithm at rest and during a maximal exercise stress test (Substudy I). 
Ten LQTS mutation carriers (5 with KCNQ1 and 5 with HERG mutations), and 11 
healthy controls performed an exercise stress test twice. The time interval between these 
ranged from 1 to 31 months, being 19 months on average.  
 
 To improve the diagnosis of LQTS, the QT and Tpe intervals were compared at pre-
specified heart rates during the exercise and recovery periods of the exercise tolerance 
test (Substudy II). Fifteen KCNQ1 (8 females), 15 HERG (8 females) and 9 SCN5A 
mutation carriers (5 females) as well as 27 healthy controls (12 females) performed the 
test. The mean ages were 34 ± 11, 41 ±10, 35 ±15, and 34 ± 7 years, respectively.  
 
4.3.2. Epinephrine bolus challenges  
 
The QT peak, QT end and Tpe intervals were examined after epinephrine bolus 
injection (Substudy III). At the highest epinephrine dose, the morphology of T wave 
was evaluated (Substudy IV). The epinephrine test was performed for 10 KCNQ1 (5 
females), 10 HERG (5 females) and 10 SCN5A mutation carriers (5 females) as well as 
for 15 healthy controls (8 females). The mean ages during the test were 36 ± 13, 42 ± 










4.3.3. Antihistamine provocation 
 
The effect of antihistamine cetirizine on ventricular repolarization was studied during 
the physical exercise test (Substudy V). LQTS mutation carriers took placebo and 
cetirizine 10 mg, and in addition, healthy controls took cetirizine 50 mg daily. The study 
was single–blinded and randomized. Subjects took capsules at home 3 days before the 
test-day; the last (fourth) dose was given at the hospital. Fifteen KCNQ1 mutation 
carriers (8 females), 15 HERG mutation carriers (8 females), and 15 healthy controls (7 
females) were included. The mean ages were 34 ± 11 years in LQT1, 41 ± 10 years in 


























5.1. Baseline values of the population 
 
There was no difference in resting heart rate or blood pressure (data not shown). QTc  
and Tpe intervals are presented in Table 3. LQTS mutation carriers had longer QTc 
intervals than healthy controls (427 ± 31 ms, and 379 ± 26 ms, respectively; p<0.001), 
but significant overlapping existed. Among LQTS carriers, the QTc interval was ≥ 440 
ms in 4/22 males, and ≥ 460 ms in 6/27 females. LQTS subgroups did not differ from 
each other by QTc interval, but LQT2 mutation carriers had longer Tpe –intervals than 




Table 3. Baseline QTc and Tpe interval values 
 
   QTc  (ms)                     QTc  (range, ms)  Tpe (ms) 
            Male      Female  
LQT1 (n=22)   416 ± 25*           367 - 430      444 - 477 79 ± 11 
LQT2 (n=17)   438 ± 32*           411 - 472      393 - 492 113 ± 24** 
LQT3 (n=10)   431 ± 38*           355 - 443      405 - 491 81 ± 17 
Controls (n=32)   379 ± 26           334 - 430      352 - 462 78 ± 10 
 









5.2. Reproducibility of QT and Tpe interval measurements 
 
5.2.1. Immediate reproducibility within the test 
 
Measurements without HR correction showed the lowest variation, whereas HR 
correction with formulas produced larger CV values. These were smaller with 
Fridericia’s than Bazett’s formula. The CV was 1.6% for QTfc and 2.4% for QTc . This 
was influenced by variation in HR, as the CV for HR was 5.5%. Overall, the CV for QT 
end intervals was 0.6%, for QT peak intervals 0.8%, and for Tpe intervals 2.3%.  
 
5.2.2. Reproducibility between separate tests 
 
The QT end and QT peak interval measurements showed similar CV values (4.4% and 
4.2%, respectively), but the Tpe interval showed slightly higher figures (10.2%) at rest. 
During the exercise stress test, the CV of the QT end and QT peak intervals determined 
at specified heart rates ranged from 2.0% to 3.4% in the whole study cohort. The range 
extended from 1.8% to 3.8% in healthy subjects, and from 1.9% to 3.4% in LQTS 
mutation carriers. The CVs of the Tpe intervals ranged from 5.9% to 11.8%. These were 
of the same magnitude between the workload and recovery phases, and in the 
subgroups. See Substudy I for details.  
 
5.3. Ventricular repolarization dynamics during exercise and recovery 
 
5.3.1. LQT1 carriers 
 
LQT1 mutation carriers had a less steep QT/HR slope (-1.0 ± 0.5) than LQT2 (-1.5 ± 
0.3; p<0.01) or LQT3 (-1.8 ± 0.4; p<0.001) carriers, indicating a weaker shortening of 
QT intervals during exercise. At high heart rates of 120-150 bpm, LQT1 mutation 
carriers had a longer QT interval than carriers of other LQTS types (p<0.01) or healthy 
controls (p<0.001). During the recovery period, LQT1 mutation carriers had a 
significantly longer QT interval than healthy controls or LQT3 carriers (p<0.01). 
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 At the beginning of exercise stress test LQT1 carriers had similar Tpe intervals to 
LQT3 carriers or healthy controls, but at higher heart rates of 140-150 bpm they had 
longer Tpe intervals (p<0.05).  
 
5.3.2. LQT2 carriers 
 
LQT2 mutation carriers showed shortening of QT interval during exercise. The QT/HR 
slope was steeper than in LQT1 carriers (-1.5 ± 0.3 and -1.0 ± 0.5, respectively; 
p<0.01). During recovery, they had a longer QT interval than LQT3 carriers or controls 
at low heart rates (p<0.05). 
 
 At the beginning of exercise at low heart rates, LQT2 mutation carriers had a longer 
Tpe interval than other LQTS type carriers or controls (p<0.001). However, LQT2 
carriers had a steeper Tpe/HR slope than LQT1 carriers (-0.54 ± 0.28 and -0.15 ± 0.43 
respectively; p<0.01), so that above a heart rate of 110 bpm they did not differ from 
LQT1 carriers.    
 
 During recovery, LQT2 carriers had a steeper Tpe/HR slope (-0.90 ± 0.50) than 
LQT1 (-0.45 ± 0.38; p<0.05) or LQT3 (-0.31 ± 0.42; p<0.01) carriers. The Tpe interval 
at low heart rates of 100-110 bpm was longer in LQT2 carriers than in LQT1 carriers 
(p<0.05), or in LQT3 carriers or healthy controls (both p<0.001). 
 
5.3.3. LQT3 carriers 
 
During exercise, the QT/HR slope was steeper in LQT3 mutation carriers than in 
controls (-1.8 ± 0.4 and  -1.3 ± 0.3, respectively; p<0.01) Nearly all LQT3 carriers 
exhibited an over 30 ms shortening in QT intervals at heart rates of 90 bpm to 100 bpm. 
At high heart rates they had a shorter Tpe interval compared to other subtypes (p<0.05), 





5.3.4. Summary of notable findings  
 
Figure 2 shows the dynamics of ventricular repolarization in the exercise stress tests. At 
the conclusion, certain cutoff values could be distinguished. At the beginning of 
exercise, at low heart rates, LQTS mutation carriers had longer QT intervals than 
healthy controls (p<0.01). At a heart rate of 90 bpm, most LQTS carriers had a QT 
interval above 370 ms, yielding a diagnostic sensitivity of 72% and specificity of 96%. 
In separating LQT3 carriers from healthy controls, this yielded a sensitivity of 86% and 
specificity of 96%. At a heart rate of 150 bpm, most of LQT1 carriers had QT interval 
above 300 ms. In separating LQT1 carriers from others, this limit had an 86% 
sensitivity and 96% specificity. In separating LQT1 carriers from other LQTS subtypes, 
sensitivity was 86% and specificity 91%. At a heart rate of 100 bpm during recovery, 
QT interval   > 340 ms showed 96% sensitivity and 85% specificity for the combined 
LQT1 and LQT2 groups. 
 
 At a heart rate of 90 bpm, most LQT2 carriers had Tpe intervals over 90 ms, showing 
83% sensitivity and 71% specificity between all others, and 83% and 70% among all 
LQTS carriers, respectively. Tpe values <70 ms showed 100% sensitivity and 75% 
specificity, thus identifying the LQT3 subtype among LQTS mutation carriers. During 
recovery at a heart rate of 100 bpm, all LQT2 carriers had Tpe intervals longer than 90 
ms. This limit had 100% sensitivity and 60% specificity in separating LQT2 mutation 


















Figure 2. QT interval and Tpe interval dynamics during exercise and recovery phases of 
exercise test in phenotypically silent LQTS mutation carriers at resting ECG. Values 






5.4. Ventricular repolarization dynamics during epinephrine provocation 
 
5.4.1. General results 
 
All doses increased the heart rate and systolic blood pressure, the highest dose showing 
the biggest effect. With the highest dose, the heart rate increased significantly (p<0.001) 
in all groups and reached 97 ± 9 bpm in LQT1, 96 ± 13 bpm in LQT2, 95 ± 17 bpm in 
LQT3 and 95 ± 8 bpm in controls, with no difference between the groups. Systolic 
blood pressure rose similarly in all groups from 126 ± 14 mmHg to 132 ± 18 mmHg 
(p<0.001), and diastolic blood pressure decreased from 78 ± 9 mmHg to 74 ± 7 mmHg 
(p<0.001).  
 
 The first three doses showed little or no effect, whereas the fourth dose showed 
measureable effects on interval lengths. Therefore, the results of 0.04 µg/kg are 
presented (Substudy III). The fifth dose gave rise to grossly abnormal T waves, 
preventing interval measurement. The morphology of the T waves was thus evaluated 
(Substudy IV).      
 
5.4.2. QT and Tpe intervals  
 
Heart rate adjusted QTc intervals at maximal heart rates increased during an epinephrine 
0.04 µg/kg bolus among all groups (Table 4). The QT peak interval was shortened, and 
Tpe interval lengthened. Interlead variation of QT end intervals (SD) between the 12 
pre-cordial ECGs was slightly increased in all groups (for LQT2, p=0.055), while the 
SD of QT peak interval was increased only in the LQT1 and LQT2 groups. 
 
 The Tpe interval increased more in the LQTS population than in controls (32 ms and 
18 ms, respectively; p<0.05) and the absolute change was largest in LQT2 (44 ms).    
 
 The interlead variation in T wave peak intervals was more pronounced in the LQTS 
population, especially in LQT1 and LQT2. Although LQT1 and LQT2 mutation carriers 
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tended to have a larger deviation in QT end intervals after epinephrine, this was not 




Table 4. QTc, Tpe, SD of QT end and SD of QT peak at baseline and during epinephrine 
(epi) 0.04 μg/kg bolus. 
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Values are presented as mean ± SD, in milliseconds. LQT1, LQT2 and LQT3 groups: 




5.4.3. T wave morphology  
 
LQTS carriers and healthy controls had different T wave morphological profiles 
(p=0.027) (Figure 3). Eighty per cent of healthy controls showed no change or 
biphasic pattern after epinephrine bolus. One healthy control expressed a slight bifid 
pattern, but showed no accompanying negative T waves. LQTS mutation carriers 
had a variety of T wave patterns, the bifid or combined pattern being the most 
   
frequent, present in 50% of cases. Normal appearing T waves were uncommon, 
present in 4/30 (13%); the biphasic pattern was more frequent, but still present in 
only 6/30 (20%) of LQTS subjects. It is noteworthy that LQT3 carriers had bifid or 
combined pattern in 6/10 (60%) of cases. The time from the injection to the 








Figure 3. T wave morphology after epinephrine bolus of 0.10 µg/kg. LQTS mutation 
carriers, n=30; healthy controls, n=15. “Combined” includes concomitant 








5.5. Ventricular repolarization during antihistamine provocation 
 
The antihistamine cetirizine did not affect resting QT interval in LQTS mutation 
carriers or in healthy subjects, even at supra-therapeutic 50 mg doses. The Tpe interval 
was slightly shortened in LQT1 (83 ± 11 ms with placebo and 76 ± 6 ms with cetirizine) 
and in LQT2 (114 ± 25 ms and 103 ± 20 ms, respectively) with a p value <0.05. 
 
 During the exercise test, LQT1 carriers had shorter QT intervals with cetirizine than 
with placebo at HR 110 bpm during workload, and at HR 140 bpm and 130 bpm during 
recovery. The Tpe interval was also shortened at HR 90, 120, 140, and 150 during 
workload, and at the highest heart rates of 140 -120 bpm during recovery. When the Tpe 
interval was shorter with cetirizine, the mean difference was 7.9 ± 2.3 ms. In LQT2 
mutation carriers, cetirizine did not have an influence on QT interval or Tpe interval 
during exercise or recovery at any HR level.  
 
 In healthy controls, QT interval was longer with cetirizine 50 mg than with placebo 
during recovery at HR 140 bpm (267 ± 16 ms with cetirizine 50 mg, 267 ± 15 ms with 
cetirizine 10 mg and 259 ± 12 ms with placebo; p<0.05). No significant change was 
observed at other heart rates. The Tpe interval was longer with cetirizine than with 
placebo at HR 140 bpm during exercise, and at  HRs 140, 130 bpm and 110 bpm during 
recovery (p<0.05). When Tpe interval was longer with cetirizine, the mean difference 
was 6.3 ± 1.5 ms between cetirizine 10 mg and placebo, and 5.0 ± 1.2 ms between 
cetirizine 50 mg and placebo. There was no difference between cetirizine 10 mg and 50 
mg. 
 
 In summary, cetirizine did not lengthen the QT interval in LQTS mutation carriers or 
in healthy subjects at rest or during exercise tests. Even at supra-therapeutic doses of 50 
mg, cetirizine did not lengthen QT intervals in healthy subjects. LQT1 carriers exhibit 
shorter Tpe intervals at rest and during exercise tests on cetirizine, whereas LQT2 
carriers had a shorter Tpe at rest, but no effect was shown during the exercise tests. In 
healthy controls, the Tpe interval was slightly longer on cetirizine at one third of 




6.1. Main observations  
 
Resting QT interval durations overlapped considerably between silent LQTS mutation 
carriers and healthy volunteers, making the diagnosis challenging. The LQTS subgroups 
cannot be separated on the basis of QTc interval length alone. LQT2 carriers had the 
longest Tpe intervals, distinguishing them from the others. During the exercise stress 
test, certain features in repolarization parameters specific to subgroups could be 
identified, enabling separation into different LQTS subtypes. LQT1 mutation carriers 
had lack of normal shortening of QT and Tpe intervals during exercise and recovery. 
LQT2 mutation carriers had proper shortening of both, and exhibited remarkably long 
Tpe intervals at low heart rates at the beginning of exercise and again at the end of 
recovery. A small epinephrine bolus lengthened the Tpe intervals further. LQT3 
mutation carriers had prominent QT and Tpe interval shortening in the exercise test, 
which distinguished them from the other LQTS subtypes. The highest epinephrine bolus 
separated LQTS mutation carriers (even LQT3 carriers) from controls. Along with QT 
interval measurement, evaluation of Tpe interval seems to add valuable diagnostic 
information about the different repolarization profiles of the LQTS subtypes. A 
combination of these tests may help to guide molecular genetic screening and 
treatments as well. 
 
 The effect of antihistamine cetirizine on ventricular repolarization was studied during 
exercise tests, which enabled intervals to be compared in certain physiological settings 
and at various heart rates. This eliminates the need for heart rate adjusting formulas, 
which should be avoided in studies involving drug effects. Cetirizine did not have 







6.2. Relation to previous studies 
 
6.2.1. Exercise tests 
 
Some earlier observations of QT interval dynamics could be repeated in this population 
of silent mutation carriers with indeterminate ECG at baseline: QT interval does not 
shorten properly in LQT1 during exercise, whereas LQT2 does show proper shortening 
and LQT3 supra-normal shortening (Vincent et al. 1991, Schwarz et al. 1995, Swan et 
al. 1999). The Tpe interval discriminated between subgroups. Takenaka et al. reported 
that heart rate adjusted Tpe intervals increase during exercise in LQT1, but not in 
LQT2, highlighting the growing transmural dispersion that occurs during exercise in 
LQT1 (Takenaka et al. 2003). In their data, Tpe intervals shortened in LQT2 patients, as 
in our study. However, our study demonstrated a discriminating value for LQT2 in the 
Tpe interval at early exercise and in late recovery. There are three main differences 
between the present study and Takenaka et al. First, our interval comparisons were 
conducted at certain heart rates without using heart rate adjusting formulas. Second, our 
study population included silent LQTS carriers, whereas 57% of the patients in 
Takenaka et al. were symptomatic with markedly prolonged QTc intervals at baseline 
(mean QTc >500 ms). Finally, we included LQT3 mutation carriers. Repolarization 
abnormalities that were evident in symptomatic patients exhibiting prolonged QTc 
intervals can be provoked in silent carriers, and a combination of QT and Tpe interval 
evaluations helps to differentiate the subgroups. 
 
6.2.2. Epinephrine tests 
 
This is the first study in which epinephrine was administered as an intravenous bolus 
injection to reveal abnormal repolarization. The group by Shimizu et al. used a bolus 
injection followed by instant infusion of epinephrine (Noda et al. 2002, Shimizu et al. 
2004). They used Bazett’s formula for adjusting the Tpe interval to the heart rate. This 
is not a validated method, as no studies for heart rate adjusting formulas for Tpe 
intervals exist. The Mayo group used only an infusion and compared QT intervals 
without heart rate correction formulas (Ackermann et al. 2002, Vyas and Ackermann 
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2006). The infusion protocols seem to be powerful in detecting carriers of LQT1, 
whereas our protocol with a small bolus helps to distinguish carriers of LQT2. Others 
studies have examined interval duration during “steady state” epinephrine infusion. The 
highest epinephrine bolus in our study caused marked, but rapidly dissolving, changes 
in T wave morphology. The T wave was also biphasic or inverted in many healthy 
controls, but the LQTS mutation carriers additionally exhibited bifid T waves. The 
phenomenon was evident in LQT3 mutation carriers too. Previous epinephrine infusion 
tests have failed to distinguish LQT3 carriers, whereas our bolus test may be used for 
this purpose.   
 
6.2.3. Drug studies in congenital LQTS 
 
Cardiovascular drugs that would be beneficial in preventing syncope and sudden cardiac 
death have been studied in congenital LQTS patients (Schwarz et al. 1995, Moss et al. 
2000). However, no non-cardiac drug tolerability has ever been clinically tested in 
known carriers of congenital LQTS before. Pre-clinical screening includes in vitro and 
in vivo studies with various expression systems, disaggregated cells, isolated tissues and 
isolated intact hearts or animals. Clinical safety studies include healthy volunteers 
and/or the target population for which the drug is being developed (Haverkamp et al. 
2000, Heist and Ruskin 2010). A commonly used antihistamine, cetirizine, had been 
carefully evaluated in previous studies, because some other previously marketed 
antihistamines (terfenadine and astemizole) had QT prolonging effects. This made it 
ethically acceptable to study cetiritzine in LQTS mutation carriers with known defects 
in ventricular repolarization. 
 
6.3. Methodological considerations 
 
There are several critical issues in studying ventricular repolarization in repeated 
measurements. The first one concerns lead selection: generally, when comparing 
measurements, the intervals should be examined in the same leads. However, the 
intervals are not always measurable in the same leads, e.g. the T wave may be so flat 
that the measurements cannot be done. Furthermore, there may be intra-individual 
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variation in QT interval duration between lead sites. Therefore, in the present study the 
measurements of several pre-cordial leads were averaged. During exercise, signals in 
some of the leads became unreadable, but remained available for measurements in 
several other channels.  
 
 Manual measurements are prone to inter- and intra-observer variations. The 
computerized method is likely to diminish observer–dependent errors. Our method was 
not totally automate, since grossly misinterpreted measurements and channels with 
noisy recordings were eliminated manually. However, the examiner could not change 
the positions of measurement points, so that absolute interval values from interpretable 
data were fully determined by the computer.    
 
 The QT interval may have some natural variation over time. In our study, long-term 
repeatability of QT intervals was better during workload and recovery phases of 
exercise test compared to rest conditions. Using plain QT interval measurements at rest, 
one cannot be certain if the minor lengthening of QT interval is natural variation over 
time or the result of drug influence. The literature shows examples of drugs that were 
developed for generally benign conditions, but that led to death due to adverse effects 
on ventricular repolarization (Simons et al. 1988, Monahan et al. 1990, Woosley et al. 
1993). Today the drugs under development are therefore examined carefully in terms of 
their QT prolonging properties. Examining QT and Tpe intervals in standardised 
physiological settings, e.g. during exercise stress tests, diminish the confounding factors 
that may modify QT intervals during plain resting measurements.  
  
 We examined and compared intervals during workload and recovery in the exercise 
stress test, which eliminated the need for heart rate corrections. In addition, there are no 
generally approved heart rate correction formulas for the Tpe interval, so comparison 
between different interventions, e.g. before and during drug therapy, should be done at 





6.4. Ventricular dispersion of repolarization in ECG  
 
It is widely accepted that the QT interval in surface ECG is a presentation of action 
potential duration, and the end of the T wave signifies the end of ventricular 
repolarization. Factors that slow ventricular repolarization also prolong the QT interval. 
Depolarization (QRS interval) duration also affects the QT interval. However, factors 
that prolong QRS intervals do not necessarily affect repolarization time. Therefore, it is 
important to focus on repolarization, the last part of which is reflected as the Tpe 
interval on surface ECG recordings. The Tpe interval is likely to be less dependent on 
QRS duration. There is also growing evidence that the dispersion of repolarization 
serves as a substrate for TdP (Yan et al. 2001, Patel et al. 2009). Thus, measuring 
changes in repolarization demands delicate examination of the QT interval and, in 
particular, the Tpe interval.  
 
 Dispersion of repolarization, estimated as the difference between the longest and the 
shortest QT interval in a standard 12-lead ECG, has been criticised and partly 
abandoned for many reasons (Gang et al. 1998, Malik and Batchvarov 2000). The last 
years have seen a remarkable increase in knowledge regarding the electrical properties 
of cardiac cells. Ventricular myocardial tissue is not homogenous, but includes at least 
three electrophysiologically and functionally distinct cell types: endocardial, epicardial 
and mid-myocardial cells (M cells) (Yan and Antzelevitch 1998). M cells are not found 
in discrete bundles or islets, and the hallmark of the M cell is the ability of its APD to 
exceed epicardial or endocardial APD (Yan et al. 1998). Studies with arterially perfused 
left ventricular free wall wedge preparations suggested that the interval between T wave 
peak and T wave end, i.e. Tpe interval, may provide a measure for transmural 
dispersion of repolarization (Yan and Antzelevitch 1998). Later, this hypothesis has 
been challenged by whole-hearts models, suggesting that the Tpe interval is not an 
index of transmural dispersion, but rather, of total dispersion of repolarization (Opthof 
et al. 2007).  
 
 In our epinephrine study, a small intravenous dose caused deviation of the T wave 
peak and end intervals among the twelve precordial leads, signifying a more chaotic 
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repolarization pattern in LQTS mutation carriers. On the other hand, healthy controls 
had smaller deviation between the channels. Deviation of repolarization of the T wave 
peak and end intervals may be explained by the earlier observations that demonstrated a 
lack of distinct M cell layers in the ventricular myocardium. Repolarization finishes 
heterogeneously in different areas of the ventricles. The Tpe interval might not be a 
marker of transmural dispersion of repolarization, but it includes various kinds of non-
homogeneities and reflects repolarization processes. Our method, which calculates the 
average of all selected precordial leads, may be a more adequate way to express the 
total dispersion of repolarization than measurement from a single lead. 
 
 An epinephrine bolus test distinguished LQT2 mutation carriers by eliciting 
prolonged Tpe intervals. The lengthened Tpe intervals may reflect early bifid T waves, 
which are more common in this subtype (Zhang et al. 2000). This is supported by the 
observation that LQT3 mutation carriers also exhibited lengthened Tpe intervals after a 
small epinephrine bolus, and after a higher epinephrine dose, exhibited obvious bifid T 
waves. The Tpe interval reflects dispersion of repolarization, as do the bifid T waves.   
 
 In our studies the Tpe interval seemed to be a more sensitive marker of disturbed 
repolarization than the plain QT interval. In exercise stress testing, the behaviour of the 
Tpe interval was specific for LQTS subtypes, separating not only the healthy controls, 
but also the different LQTS subtypes that were examined. In the epinephrine study, a 
small bolus injection affected the Tpe interval differently among the different subtypes. 
Besides the QT interval measurements, we propose measuring the Tpe interval, since it 
seems to contain additional information about the repolarization process and dispersion, 
whereas QT intervals reflect only the global end of repolarization.  
 
6.5. Practical implications 
 
Misdiagnosis of LQTS patients as healthy individuals poses a serious problem, since 
such individuals may be at risk for sudden cardiac death. Conversely, misclassifying 
non-carriers as affected can lead to substantial anxiety and inappropriate treatment 
(Vincent et al. 1992). Genetic testing reveals some of the carriers, but clinical 
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evaluation still has an important role as well. Exercise stress testing is a non-invasive 
and safe tool for evaluating ventricular repolarization, and it is currently recommended 
for all suspected cases. Although the Tpe interval has been recognized and studied for a 
number of years, to our knowledge it is not a commonly measured parameter in clinics. 
Nothing prevents it from being used in everyday clinical practice to assess congenital or 
acquired LQTS, in resting conditions and during exercise tests. This study suggests 
certain cut-off values for QT and Tpe –intervals, although the small group size restricts 
their use as reference values.   
 
 Epinephrine tests can also be safely performed in cases of suspected LQTS, though it 
is somewhat more complicated to carry out due to its pharmacological nature. A 
standard 12-lead ECG may be used, provided that a continuous ECG recording is 
available, as the BSPM recordings are limited to research use only. We recommend that 
the test be performed in a hospital environment and interpreted by a cardiologist with 
experience in this particular field. 
 
 Regulatory authorities have expended much effort in diminishing the risks of 
acquired LQTS. Extensive preclinical studies on ventricular repolarization are of major 
importance in the preclinical safety assessments of new compounds. However, the 
effects on repolarization on congenital LQTS mutation carriers are never studied, 
although LQTS mutations may be prevalent in the general population and despite it 
could be possible in carefully observed conditions. Naturally, it would be unethical to 
expose symptomatic patients with long QT intervals to drugs that would potentially 
even further prolong the QT interval. However, silent carriers may be studied, while 
bearing in mind that this population may be subject to a further worsening of ventricular 










Examining multiple BSPM leads, calculating the average of these leads, and comparing 
interval values in a standardized physiological setting at the same heart rates produces 
highly reproducible and accurate measurements.  
 
 The Tpe interval is a more sensitive marker than QT interval duration. The Tpe 
interval signifies the repolarization process, whereas the QT interval signifies the global 
ending of ventricular repolarization.  
 
 Physical exercise stress tests and epinephrine tests are safe, non-invasive techniques 
that help in diagnosing LQTS mutation carriers and in making diagnostic distinctions 
between subtypes when resting ECG alone is not of sufficient diagnostic value.  
 
 Long QT interval durations during exercise and recovery from exercise stress testing 
may reveal subtype 1 of LQTS, with unusual lack of shortening of Tpe interval 
providing support for the diagnosis. Type 2 LQTS can be identified by having long Tpe 
intervals at low heart rates and proper shortening of both Tpe and QT intervals at 
elevated heart rates. Abrupt lengthening of Tpe intervals in epinephrine testing is typical 
for LQT2. Type 3 LQTS may be exposed by short Tpe intervals in exercise stress tests 
and bifid T waves in epinephrine challenge tests. 
 
 Finally, the validated QT and Tpe interval measurement method was shown to be 
useful in assessing the effects of pharmacological interventions on ventricular 
repolarization. Using this method, it was demonstrated that cetirizine at recommended 
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